Clinical Effectiveness of Rivastigmine Monotherapy and Combination Therapy in Alzheimer's Patients.

CONCLUSION: Poor metabolizer subjects of UGT2B7 polymorphism in patients under rivastigmine combination therapy have higher drug levels with a poor response to the drug treatments. PMID: 23206182 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/PubMed/23206182?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - December 4, 2012 Category: Neuroscience Authors: Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V Tags: CNS Neurosci Ther Source Type: research